Athenex Inc (ATNX) is a Global Biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. They are working to bring innovative cancer treatments (Oral Taxil) to the market and improve health outcomes. Senior members of the Laidlaw Capital markets team have had a long standing relationship with ATNX for years but the team officially started working with ATNX in 2H2017. What we realized was that while ATNX had a robust pipeline, many supportive shareholders in Asia, a stellar CEO and an exciting story, they seemed to be under the radar and in our opinion under-valued. We initiated coverage in September of 2017 and quickly rolled our sleeves up and started making relevant introductions. Since 2H2017, the Laidlaw Capital Markets team, has hosted more than 50 Meetings and calls for the company. In the process of making these introductions, we were able to add over 10 new page 1 and page 2 shareholders to the company’s cap table with tier 1 marquee name Healthcare centric institutional investors, who collectively have invested over $250mm into the company. In 1Q2018, ATNX raised $75mm in a follow-on offering lead by RBC, DB and Needham. Laidlaw acted as a co-manager on the transaction. Then in mid-2018, after facilitating many meetings with an investor who continues to be a supportive page 1 holder, we were exclusive placement agent on a $100,000,000 Debt and equity Hybrid private placement for ATNX. This was the largest debt and equity Hybrid transaction the fund had done to date and a huge win for ATNX not just from a balance sheet perspective but for their brand as well. In addition to the follow-on offering and private placement, Laidlaw effected a multiple block trade.